- Nordic Bioscience, Herlev Hovedgade, DK-2730, Herlev, Denmark.
Abstract
Ethical,
clinical and economic considerations highlight the pressing need to
advance the identification of optimal treatments for each individual
patient. PHC may provide significant benefit in the treatment of a
number of clinical indications, characterised by costly therapy, low
response rates and significant problems associated with trial and error
prescription, including the risk of serious side effects. As an example
we will focus on the promise of PHC for the field of rheumatology, in
particular in the use of diagnostic practice in guiding the treatment of
rheumatoid arthritis (RA). While RA may seem a disease optimally suited
for PHC, some stakeholders question the need, possibilities and
benefits of such practice. In this review we offer a deconstruction of
the application of novel predictive diagnostics on the practice of
medicine in RA. We will outline the opportunities, the current success,
and lack of the same, across the RA field and attempt to outline
emerging opportunities that benefit patients, physicians, healthcare
payers and the pharmaceutical industry in assuring the right patients
are treated with the right drug.
No comments:
Post a Comment